Preclinical studies of group A streptococcal vaccine candidates [ 2010 - 2012 ]

Research Grant

Researchers: Prof Mark Walker (Principal investigator) ,  Dr Michael Batzloff ,  Prof Bostjan Kobe

Brief description Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified 2 new protective candidate antigens, and we seek to undertake critical preclinical studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Wyeth) leading to human trials and the development of a safe group A streptococcal vaccine for human use.

Funding Amount $AUD 532,492.93

Funding Scheme NHMRC Development Grants

Notes Development Grant